Journal
PHARMACEUTICALS
Volume 3, Issue 10, Pages 3101-3126Publisher
MDPI
DOI: 10.3390/ph3103101
Keywords
endocannabinoids; schizophrenia; cannabis; drug abuse; metabolism
Categories
Funding
- Canadian Institutes of Health Research
- Fonds de Recherche en Sante du Quebec
Ask authors/readers for more resources
The endocannabinoids anandamide and 2-arachydonoylglycerol (2-AG) are lipids naturally derived from membrane precursors which bind cannabinoid receptors (CB1, CB2). This endocannabinoid system is disturbed in schizophrenia. Indeed, there seems to be an association between schizophrenia and polymorphisms of the CB1 receptor gene. Moreover, CB1 receptors are found in higher density in the prefrontal cortex, hippocampus and basal ganglia of patients with schizophrenia. Similarly, anandamide levels are increased in the cerebrospinal fluid (CSF) and in the serum of schizophrenia patients, including during the prodromal state, suggesting that they may play a protective role in psychosis homeostasis. Future studies are needed to further explore the role of the endocannabinoid system in the pathophysiology of schizophrenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available